ES2104938T3 - Metodo de inhibir la fibrosis. - Google Patents

Metodo de inhibir la fibrosis.

Info

Publication number
ES2104938T3
ES2104938T3 ES92917284T ES92917284T ES2104938T3 ES 2104938 T3 ES2104938 T3 ES 2104938T3 ES 92917284 T ES92917284 T ES 92917284T ES 92917284 T ES92917284 T ES 92917284T ES 2104938 T3 ES2104938 T3 ES 2104938T3
Authority
ES
Spain
Prior art keywords
formula
fibrosis
alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917284T
Other languages
English (en)
Inventor
Saood Murad
Sheldon R Pinnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2104938T3 publication Critical patent/ES2104938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA INHIBIR LA FIBROSIS EN UN SUJETO HUMANO O ANIMAL AFECTADO CON UNA ENFERMEDAD FIBROSANTE. EL METODO COMPRENDE LA ADMINISTRACION AL SUJETO DE UNA CANTIDAD EFECTIVA PARA LA INHIBICION DE LA FIBROSIS DE UN COMPUESTO DE LA FORMULA I EN LA QUE: N ES 1 O 2, R SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE HIDROGENO, ALQUIL C1-C4, HIDROXIDO, AMINO Y NITRO; R1 SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE HIDROGENO, Y ALQUIL C1-C4 O LAS SALES FARMACEUTICAMENTE ACEPTABLES DEL COMPUESTO. UN COMPUESTO MUY ADECUADO DE LA FORMULA I ES LA HIDRACIDA BENZOICA. TAMBIEN SE PRESENTAN FORMULACIONES FARMACEUTICAS Y EL USO DE LOS COMPUESTOS I PARA FABRICAR LAS MISMAS.
ES92917284T 1991-04-01 1992-03-31 Metodo de inhibir la fibrosis. Expired - Lifetime ES2104938T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67847291A 1991-04-01 1991-04-01

Publications (1)

Publication Number Publication Date
ES2104938T3 true ES2104938T3 (es) 1997-10-16

Family

ID=24722926

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917284T Expired - Lifetime ES2104938T3 (es) 1991-04-01 1992-03-31 Metodo de inhibir la fibrosis.

Country Status (11)

Country Link
US (2) US5374660A (es)
EP (1) EP0581904B1 (es)
JP (1) JPH06506471A (es)
AT (1) ATE153500T1 (es)
AU (1) AU652644B2 (es)
CA (1) CA2107371A1 (es)
DE (1) DE69220050T2 (es)
DK (1) DK0581904T3 (es)
ES (1) ES2104938T3 (es)
GR (1) GR3024548T3 (es)
WO (1) WO1992017065A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0581904T3 (da) * 1991-04-01 1997-12-29 Univ Duke Fremgangsmåde til inhibering af fibrose
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6117445A (en) * 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
DK2712617T3 (en) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Treatment of fibrosis with Fxr ligands.
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
DK2953948T3 (en) 2013-02-07 2017-12-18 Scifluor Life Sciences Inc FLUORINATED INTEGRIN ANTAGONISTS
RU2017132433A (ru) 2015-02-19 2019-03-19 Сайфлуор Лайф Сайенсиз, Инк. Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение
CN108040467A (zh) 2015-04-30 2018-05-15 赛弗卢尔生命科学公司 四氢萘啶基丙酸衍生物及其用途
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB828344A (en) * 1957-01-30 1960-02-17 Ici Ltd Veterinary compositions containing acid hydrazides
JPS5119135A (en) * 1974-08-05 1976-02-16 Itsuo Takeshita Kohakusenzaino seiho
US4321273A (en) * 1978-03-01 1982-03-23 Ryuichi Sato Germanium-containing organic polymer and its use in the treatment of pulmonary fibrosis
US4382941A (en) * 1980-11-26 1983-05-10 Sicardi Susana M Bishydrazide quaternary salts and pharmaceutical compositions thereof
HU207051B (en) * 1987-12-30 1993-03-01 Chinoin Gyogyszer Es Vegyeszet Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds
DK0581904T3 (da) * 1991-04-01 1997-12-29 Univ Duke Fremgangsmåde til inhibering af fibrose

Also Published As

Publication number Publication date
DK0581904T3 (da) 1997-12-29
DE69220050D1 (de) 1997-07-03
AU652644B2 (en) 1994-09-01
US5374660A (en) 1994-12-20
CA2107371A1 (en) 1992-10-02
GR3024548T3 (en) 1997-12-31
AU1876392A (en) 1992-11-02
WO1992017065A2 (en) 1992-10-15
EP0581904A4 (en) 1994-05-25
WO1992017065A3 (en) 1992-11-26
ATE153500T1 (de) 1997-06-15
EP0581904A1 (en) 1994-02-09
EP0581904B1 (en) 1997-05-28
US5571846A (en) 1996-11-05
JPH06506471A (ja) 1994-07-21
DE69220050T2 (de) 1998-01-22

Similar Documents

Publication Publication Date Title
TW255881B (es)
KR890005124A (ko) 세펨 화합물 및 이의 제조방법
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ES2104938T3 (es) Metodo de inhibir la fibrosis.
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
HU9403809D0 (en) Substituted (arylalkylaminobenzyl)-aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents
ZA932025B (en) Agents for use as an anti-irritant
DE3460841D1 (en) Mercaptoacetic acid and 3-mercaptopropionic acid amide derivatives for use in treatment of a human or animal body, some new derivatives and pharmaceutical compositions containing them
NO950177D0 (no) Farmakologisk aktive erivater
ZA916977B (en) Pharmaceutical compositions for use in treating aids
DE3885978D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 581904

Country of ref document: ES